Date | Time | Source | Headline | Symbol | Company |
07/22/2024 | 11:59AM | Business Wire | Lawyers for Ovarian Cancer Victims Urge NO Vote on J&J’s Latest Bankruptcy Plan | NYSE:JNJ | Johnson and Johnson |
07/22/2024 | 8:00AM | PR Newswire (US) | Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depression | NYSE:JNJ | Johnson and Johnson |
07/17/2024 | 8:14AM | Edgar (US Regulatory) | Form 8-K - Current report | NYSE:JNJ | Johnson and Johnson |
07/17/2024 | 6:30AM | IH Market News | Tech-Led Decline in U.S. Index Futures Pre-Market, Oil Prices Steady After U.S. Inventory Drop | NYSE:JNJ | Johnson and Johnson |
07/17/2024 | 6:28AM | IH Market News | Spirit Airlines Cuts Revenue Forecast, J.B. Hunt Disappoints Analysts’ Estimates, and More Earnings Updates | NYSE:JNJ | Johnson and Johnson |
07/17/2024 | 6:25AM | Business Wire | Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2024 | NYSE:JNJ | Johnson and Johnson |
07/17/2024 | 6:20AM | Business Wire | Johnson & Johnson reports Q2 2024 results | NYSE:JNJ | Johnson and Johnson |
07/11/2024 | 7:30AM | Business Wire | Johnson & Johnson Strengthens Pipeline to Lead in Atopic Dermatitis With the Completion of the Acquisition of Yellow Jersey Therapeutics, Gaining Ownership of NM26 | NYSE:JNJ | Johnson and Johnson |
07/09/2024 | 5:48PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NYSE:JNJ | Johnson and Johnson |
07/03/2024 | 8:00AM | PR Newswire (Canada) | Santé Canada autorise le traitement par RYBREVANT® (amivantamab) en association avec le carboplatine et le pemetrexed comme seul traitement de première intention ciblé approuvé pour les patients atteints d'un cancer du poumon non à petites cellules p | NYSE:JNJ | Johnson and Johnson |
07/03/2024 | 8:00AM | PR Newswire (Canada) | Health Canada Authorizes RYBREVANT® (amivantamab) in Combination with Carboplatin and Pemetrexed as the Only Targeted First-line Treatment Approved for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations | NYSE:JNJ | Johnson and Johnson |
07/02/2024 | 7:30AM | PR Newswire (US) | CARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 study | NYSE:JNJ | Johnson and Johnson |
06/28/2024 | 11:30AM | PR Newswire (US) | Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients | NYSE:JNJ | Johnson and Johnson |
06/27/2024 | 6:46PM | Business Wire | Lawyers for Johnson & Johnson’s Ovarian Cancer Victims React to SCOTUS Decision in Purdue | NYSE:JNJ | Johnson and Johnson |
06/21/2024 | 7:30AM | Business Wire | Johnson & Johnson Completes Acquisition of Proteologix, Inc. | NYSE:JNJ | Johnson and Johnson |
06/20/2024 | 4:30PM | PR Newswire (US) | Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn's disease | NYSE:JNJ | Johnson and Johnson |
06/20/2024 | 1:07PM | Business Wire | More than 60 Law Firms Oppose J&J Prepack Bankruptcy Scheme | NYSE:JNJ | Johnson and Johnson |
06/20/2024 | 8:00AM | PR Newswire (US) | TREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous induction | NYSE:JNJ | Johnson and Johnson |
06/20/2024 | 6:55AM | IH Market News | Trump Media Resells Stocks and Warrants; KB Home Exceeds Q2 Expectations, and More News | NYSE:JNJ | Johnson and Johnson |
06/17/2024 | 5:55PM | Business Wire | Beasley Allen and Levin Papantonio: Leading Law Firms Seek Protection for Future Victims of Johnson & Johnson Talc Products | NYSE:JNJ | Johnson and Johnson |
06/17/2024 | 8:00AM | PR Newswire (US) | Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer | NYSE:JNJ | Johnson and Johnson |
06/15/2024 | 3:30AM | PR Newswire (US) | Late-breaking results show nipocalimab significantly improves Sjögren's disease activity in a Phase 2 study | NYSE:JNJ | Johnson and Johnson |
06/14/2024 | 8:00AM | PR Newswire (US) | TALVEY® (talquetamab-tgvs) demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma | NYSE:JNJ | Johnson and Johnson |
06/12/2024 | 2:26PM | Business Wire | Talc Plaintiffs File Motion for Temporary Restraining Order to Limit Johnson & Johnson’s Use of Bankruptcy Strategy | NYSE:JNJ | Johnson and Johnson |
06/12/2024 | 7:19AM | IH Market News | Paramount Ends Skydance Talks, Oracle Shares Surge 8.7% on New Partnerships, and More News | NYSE:JNJ | Johnson and Johnson |
06/06/2024 | 5:07PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NYSE:JNJ | Johnson and Johnson |
06/06/2024 | 5:07PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NYSE:JNJ | Johnson and Johnson |
06/05/2024 | 7:41AM | IH Market News | Apollo Buys 49% of Intel’s Irish Plant for $11bn, BlackRock and Citadel to Create Texas Exchange, and More News | NYSE:JNJ | Johnson and Johnson |
06/04/2024 | 4:30PM | Business Wire | Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results | NYSE:JNJ | Johnson and Johnson |
05/31/2024 | 8:45AM | Business Wire | Johnson & Johnson Completes Acquisition of Shockwave Medical | NYSE:JNJ | Johnson and Johnson |